Journal: bioRxiv
Article Title: Pseudohypoxia-stabilized HIF2⍺ transcriptionally inhibits MNRR1, a druggable target in MELAS
doi: 10.1101/2024.10.07.617011
Figure Lengend Snippet: A: Above , Equal amounts of MELAS cell lysates, treated with vehicle (DMSO) or increasing amounts of tizoxanide (2.5 to 40 μM) for 24 h, were separated on an SDS-PAGE gel and probed for HIF2α, MNRR1, and Tubulin. Below, Protein quantification for MNRR1 and HIF2α relative to Tubulin. B: Dual luciferase reporter assay showing relative activation of MNRR1 -luciferase in MELAS cybrid cells overexpressing WT , Δ 801-952 , ΔORE (sequence in orange in ) or ΔHRE (sequence in red in ). C: Dual luciferase reporter assay showing relative activation of HRE -luciferase levels in cybrid cells with 0% (CL9) and 70% MELAS heteroplasmy (DW7). D : Dual luciferase reporter assay showing relative activation of MNRR1 -luciferase levels in MELAS cybrid cells with 0% heteroplasmy (CL9) overexpressing EV (empty vector) or HIF2α. E: Sequences in MNRR1 promoter highlighting the binding sites for RBPJκ (orange) and HIF2α (blue) on opposite strands of DNA. In all figures, * indicates p<0.05, ** indicates p<0.005.
Article Snippet: Tizoxanide, nitazoxanide, and genetisate were obtained from Selleckchem (Houston, TX), Phenyl-4-aminosalicylic acid was obtained from A2Bchem (San Diego, CA), 2-Amino 5-nitrothiazole was from Sigma, and the remaining compounds (4-Aminobenzanilide, 4-Amino salicylic acid, benzanilide, phenyl benzoate, and phenyl salicylic acid) were from Santa Cruz Biotechnology (Dallas, TX).
Techniques: SDS Page, Luciferase, Reporter Assay, Activation Assay, Sequencing, Plasmid Preparation, Binding Assay